Evommune (EVMN) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immuneering is the larger company by market cap ($242.0 million vs $232.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | IMRX |
|---|---|---|
| Share price | $6.41 | $3.74 |
| Market cap | $232.63M | $241.97M |
| 1-day change | +3.05% | -3.11% |
| YTD return | -62.56% | -43.16% |
| 1-year return | — | -42.46% |
| 5-year return | — | -84.96% |
| EPS (TTM) | $-3.75 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $8.48 |
| 52-week low | $6.02 | $3.60 |
| Distance from 52-week high | -80.69% | -55.90% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +276.44% | +359.09% |
| Average volume | 697.98K | 694.54K |
| Shares outstanding | 36.29M | 64.70M |
| Employees | 48 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
EVMN vs IMRX FAQ
Which is bigger, Evommune or Immuneering?
Immuneering (IMRX) is larger, with a market capitalization of $241.97M compared with $232.63M for Evommune (EVMN).
Are Evommune and Immuneering in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.